Takeda Pharmaceutical Files Routine 6-K Report
Ticker: TKPHF · Form: 6-K · Filed: May 28, 2025 · CIK: 1395064
| Field | Detail |
|---|---|
| Company | Takeda Pharmaceutical Co Ltd (TKPHF) |
| Form Type | 6-K |
| Filed Date | May 28, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, compliance, foreign-private-issuer
TL;DR
Takeda filed a standard 6-K, no new info, just compliance.
AI Summary
Takeda Pharmaceutical Company Limited filed a Form 6-K on May 28, 2025, reporting its activities for the month of May 2025. This filing is a routine report for foreign private issuers and does not contain specific financial or operational updates beyond its submission status.
Why It Matters
This filing indicates Takeda is fulfilling its reporting obligations as a foreign private issuer in the U.S. market. It does not provide new material information.
Risk Assessment
Risk Level: low — This is a routine administrative filing by a foreign private issuer and does not contain new material information that would impact risk.
Key Players & Entities
- Takeda Pharmaceutical Company Limited (company) — Filer of the 6-K report
- 0001395064-25-000063 (other) — Accession number for the filing
- 001-38757 (other) — SEC file number for Takeda
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, used to furnish information which the registrant may be required to disclose or make public in its home country.
What period does this specific 6-K filing cover?
This Form 6-K is for the month of May 2025.
Is Takeda Pharmaceutical Company Limited a U.S. or foreign issuer?
Takeda Pharmaceutical Company Limited is identified as a foreign private issuer.
Does this filing indicate Takeda is submitting its annual report?
No, this filing is a Form 6-K, and Takeda indicates it files annual reports under Form 20-F, not this form.
What is the principal executive office address for Takeda?
The principal executive offices are located at 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo 103-8668, Japan.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 28, 2025 regarding TAKEDA PHARMACEUTICAL CO LTD (TKPHF).